Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT

Journal of the Neurological Sciences

Volumn 256, Issue 1-2, 2007, Pages 52-60

  Oishi, Naoya ^a   Hashikawa, Kazuo ^a   Yoshida, Hidefumi ^a,b   Ishizu, Koichi ^a   Ueda, Masashi ^c,d   Kawashima, Hidekazu ^a   Saji, Hideo ^c   Fukuyama, Hidenao ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shiga Medical Center for Adults   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

5 123I iodo 3 (2(S) azetidinylmethoxy)pyridine; Distribution volume; Dopamine agonist; Nicotinic acetylcholine receptors; Parkinson's disease; Single photon emission computed tomography

Indexed keywords

5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; AMANTADINE; AZETIDINE DERIVATIVE; CABERGOLINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; IODINE 123; LEVODOPA; NICOTINIC RECEPTOR; PERGOLIDE; PYRIDINE DERIVATIVE; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN REGION; BRAIN STEM; CEREBELLUM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DISTRIBUTION VOLUME; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; NEUROIMAGING; OCCIPITAL CORTEX; OUTCOME ASSESSMENT; PARIETAL LOBE; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE; TISSUE DISTRIBUTION; TREATMENT DURATION; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AZETIDINES; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PARKINSON DISEASE; PYRIDINES; RECEPTORS, NICOTINIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34147108303     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.02.014     Document Type: Article

References (37)

1. Gotti C., and Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74 (2004) 363-396
2. Pimlott S.L., Piggott M., Owens J., Greally E., Court J.A., Jaros E., et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 29 (2004) 108-116
3. Rinne J.O., Myllykyla T., Lonnberg P., and Marjamaki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 547 (1991) 167-170
4. Marshall D.L., Redfern P.H., and Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68 (1997) 1511-1519
5. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 20 (1997) 92-98
6. Clarke P.B., and Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348 (1985) 355-358
7. Saji H., Ogawa M., Ueda M., Iida Y., Magata Y., Tominaga A., et al. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 16 (2002) 189-200
8. Ueda M., Iida Y., Mukai T., Mamede M., Ishizu K., Ogawa M., et al. 5-[123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 18 (2004) 337-344
9. Fujita M., Ichise M., van Dyck C.H., Zoghbi S.S., Tamagnan G., Mukhin A.G., et al. Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 30 (2003) 1620-1629
10. Mamede M., Ishizu K., Ueda M., Mukai T., Iida Y., Fukuyama H., et al. Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J Nucl Med 45 (2004) 1458-1470
11. Fujita M., Ichise M., Zoghbi S.S., Liow J.S., Ghose S., Vines D.C., et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 59 (2006) 174-177
12. Quik M., Bordia T., Okihara M., Fan H., Marks M.J., McIntosh J.M., et al. l-DOPA treatment modulates nicotinic receptors in monkey striatum. Mol Pharmacol 64 (2003) 619-628
13. Hughes A.J., Ben-Shlomo Y., Daniel S.E., and Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 (1992) 1142-1146
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-IV (1994), American Psychiatric Association, Washington, DC
15. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
16. Fahn S., Elton R.L., and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S., Marsden C.D., Calne D.B., and Lieberman A. (Eds). Recent development in Parkinson's disease (1987), Macmillan Health Care Information, Florham Park, NJ 153-163
17. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
18. Oishi N., Udaka F., Kameyama M., Sawamoto N., Hashikawa K., and Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65 (2005) 1708-1715
19. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10 (1990) 740-747
20. Alpert N.M., Eriksson L., Chang J.Y., Bergstrom M., Litton J.E., Correia J.A., et al. Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab 4 (1984) 28-34
21. Friston K.J., Holmes A.P., Worsley K.J., Poline J.B., Frith C.D., and Frackowiak R.S. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2 (1995) 189-210
22. Talairach J., and Tournoux P. Co-planar stereotaxic atlas of the human brain (1988), Thieme, Stuttgart
23. Picciotto M.R., and Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 53 (2002) 641-655
24. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., JT, and OB. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127 (2004) 791-800
25. Pahapill P.A., and Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 123 (2000) 1767-1783
26. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64 (1995) 385-395
27. Taylor A.E., Saint-Cyr J.A., and Lang A.E. Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain 109 (1986) 845-883
28. Forgacs P.B., and Bodis-Wollner I. Nicotinic receptors and cognition in Parkinson's Disease: the importance of neuronal synchrony. J Neural Transm 111 (2004) 1317-1331
29. Le Moal M., and Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 71 (1991) 155-234
30. Ouchi Y., Yoshikawa E., Okada H., Futatsubashi M., Sekine Y., Iyo M., et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 45 (1999) 601-610
31. Cao Y.J., Surowy C.S., and Puttfarcken P.S. Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology 48 (2005) 72-79
32. Quik M., Vailati S., Bordia T., Kulak J.M., Fan H., McIntosh J.M., et al. Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA. Mol Pharmacol 67 (2005) 32-41
33. DeBoer P., and Abercrombie E.D. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J Pharmacol Exp Ther 277 (1996) 775-783
34. Aosaki T., Kiuchi K., and Kawaguchi Y. Dopamine D1-like receptor activation excites rat striatal large aspiny neurons in vitro. J Neurosci 18 (1998) 5180-5190
35. Garcia-Colunga J., and Miledi R. Effects of serotonergic agents on neuronal nicotinic acetylcholine receptors. Proc Natl Acad Sci U S A 92 (1995) 2919-2923
36. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 (2001) S1-S88
37. Firbank M.J., Colloby S.J., Burn D.J., McKeith I.G., and O'Brien J.T. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 20 (2003) 1309-1319